If you had looked at Ambu in late October 2025, with bullish and bearish analysts arguing over whether single-use endoscopy expansion or rising costs would define its future, it might have felt like a coin toss. Holding Ambu over the past year would have meant a 23.9% loss, including dividends. If you were weighing that decision then, which assumption on record about regulation, pricing pressure or growth would you have tested harder?
Ambu has already moved. Pinpoint other ways to investigate the theme among 123 healthcare AI stocks.
The Two Ambu Stories Investors Had To Weigh
The shares cost DKK108 at the start of the period, and Ambu sat between two sharply different but credible stories about single-use endoscopy.
On the optimistic side, the bullish view argued that expanding disposable scopes and first-mover advantages would lift hospital efficiency. Its Fair Value was DKK131, a notional price if that growth path and margin improvement thesis played out.
The bearish story put more weight on rising costs and rivals. It used a Fair Value of DKK90 and focused on tighter healthcare budgets and stricter rules squeezing prices and profitability.
What The Results Changed For The Ambu Debate
The clearest new fact was Ambu’s Q3 2026 report. Revenue reached DKK1,640m and net income came in at DKK156m, with net margin at 9.5% versus 8.2% a year earlier. That margin shift supported the optimistic thesis that disposable endoscopy could support profitability, although it did not rule out future pressure on pricing or costs.
The practical lesson is simple. When a growth story hinges on better profitability, focus on reported net margin and absolute earnings, and compare them with earlier periods and the original thesis rather than with the share price chart.
What Ambu’s Lower Price Asks You To Believe
Ambu trades at DKK80.45 today, after the share price fell 23.9% over the past year from DKK108. The selected Narrative’s Fair Value sits above the current price and ties that gap to how well the business turns its single use endoscopy push into durable earnings.
The argument leans on Ambu extending procedure coverage and sharpening its manufacturing efficiency, particularly in Mexico and Asia. For that higher figure to make sense, a buyer today would need to believe Ambu can keep converting reusable procedures to single use while protecting its premium positioning and margins.
"Key Takeaways: Bullish analysts expect Ambu to keep converting more endoscopy procedures from reusable to single use while expanding its EndoIntelligence platform, so that Endoscopy Solutions remains the main driver of revenue and margin progress. The main thing that has to go right is that Ambu continues to execute on manufacturing efficiency gains in Mexico and Asia while holding its premium positioning in single use endoscopy, despite slower than hoped share gains in some urology procedures and low single digit growth in Anesthesia & Patient Monitoring."
The price and this Narrative do not agree. → Uncover what this Narrative says Ambu is actually worth
Looking One Step Beyond Ambu
Ambu is a story about single use scopes. One step away, hospitals face a different question. How do you make complex procedures less invasive without losing control?
Another player pushed into robotic systems built for that problem. Its machines let surgeons work through tiny access points while seeing more and reaching further.
Once those robots entered operating rooms, the focus shifted. The real value moved toward instruments, software and constant training around each system.
For anyone studying Ambu, that shift is worth noting. Disposable scopes and robotic platforms both chase procedure volume, yet they monetize reliability and learning in very different ways.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 18% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com